Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.53 +0.9%	$3.50	$2.45 ▼ $4.14	$280.14M	0.25	385,271 shs	343,802 shs
MGEN Miragen Therapeutics	$18.54 +0.5%	$17.69	$4.66 ▼ $34.05	$72.45M	1.66	134,027 shs	891,716 shs
NKTR Nektar Therapeutics	$27.43 +0.6%	$21.08	$6.45 ▼ $37.38	$521.72M	0.95	858,487 shs	659,562 shs
OPGN OpGen		$3.34	$0.00 ▼ $5.25	$1K	-1.77	8,778 shs	N/A

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	+3.55%	+4.17%	+24.56%	-4.89%
MGEN Miragen Therapeutics	0.00%	+12.98%	+8.74%	+43.28%	+19.69%
NKTR Nektar Therapeutics	0.00%	+18.21%	+9.30%	+161.49%	+45.39%
OPGN OpGen	0.00%	-99.75%	-100.00%	-100.00%	-100.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.2769 of 5 stars	3.3	0.0	0.0	0.0	2.5	2.5	1.3
MGEN Miragen Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	4.3394 of 5 stars	3.4	4.0	0.0	4.2	3.0	2.5	0.0
OPGN OpGen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	69.97% Upside
MGEN Miragen Therapeutics	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	222.03% Upside
OPGN OpGen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MGEN, OPGN, NKTR, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
MGEN Miragen Therapeutics	$4.46M	16.25	N/A	N/A	$6.78 per share	2.73
NKTR Nektar Therapeutics	$98.43M	5.30	N/A	N/A	$4.94 per share	5.55
OPGN OpGen	$2.67M	0.00	N/A	N/A	($11.55) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
MGEN Miragen Therapeutics	-$41.87M	-$20.09	N/A	N/A	N/A	-1,393.50%	-141.66%	-88.74%	N/A
NKTR Nektar Therapeutics	-$118.96M	-$8.80	N/A	N/A	N/A	-163.17%	-631.43%	-58.21%	11/6/2025 (Estimated)
OPGN OpGen	-$32.67M	N/A	0.00	N/A	N/A	-1,140.36%	N/A	-287.58%	N/A

Latest MGEN, OPGN, NKTR, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	Q2 2025	NKTR Nektar Therapeutics	-$3.13	-$2.95	+$0.18	-$2.95	$9.42 million	$11.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGEN Miragen Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OPGN OpGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
MGEN Miragen Therapeutics	0.20	4.23	4.23
NKTR Nektar Therapeutics	N/A	2.61	2.61
OPGN OpGen	N/A	5.45	5.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
MGEN Miragen Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%
OPGN OpGen	2.68%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
MGEN Miragen Therapeutics	1.10%
NKTR Nektar Therapeutics	3.71%
OPGN OpGen	43.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
MGEN Miragen Therapeutics	45	3.91 million	N/A	Not Optionable
NKTR Nektar Therapeutics	220	19.02 million	18.31 million	Optionable
OPGN OpGen	100	10.07 million	4.70 million	Not Optionable

MGEN, OPGN, NKTR, and AVIR Headlines

Recent News About These Companies

OpGen Delays Filing of Quarterly Report

August 14, 2025 | tipranks.com

OpGen Forms Joint Venture with European Bank

May 29, 2025 | tipranks.com

OpGen Delays 10-Q Filing Amid Operational Challenges

May 16, 2025 | tipranks.com

OpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital Ltd

December 11, 2024 | nl.investing.com

OpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoen

December 10, 2024 | nl.investing.com

OpGen Appoints New COO and Company Secretary

December 6, 2024 | tipranks.com

OpGen (OTC:OPGN) Stock Quotes, Forecast and News Summary

October 5, 2024 | benzinga.com

OPGN Stock Earnings: OpGen Reported Results for Q2 2024

August 21, 2024 | investorplace.com

OPGN Stock Earnings: OpGen Reported Results for Q1 2024

July 8, 2024 | investorplace.com

OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023

June 5, 2024 | investorplace.com

Opgen Inc (NASDAQ:OPGN) stock Posted Gross Margin of 6.62 percent in Last Year: Is Justifiable?

May 27, 2024 | bovnews.comB

OpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

May 25, 2024 | finanznachrichten.de

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

May 24, 2024 | globenewswire.com

OpGen to Execute 1-for-10 Reverse Stock Split

May 16, 2024 | 360dx.com3

OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split

May 16, 2024 | finanznachrichten.de

OpGen Announced 1-for-10 Reverse Stock Split

May 16, 2024 | globenewswire.com

OpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo Finance

May 4, 2024 | uk.finance.yahoo.com

OpGen, Inc.: OpGen Provides Update on Business Operations and Strategic Opportunities

April 30, 2024 | finanznachrichten.de

OpGen Provides Update on Business Operations and Strategic Opportunities

April 29, 2024 | globenewswire.com

OpGen CEO David Lazar buys additional shares worth $150k

April 27, 2024 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MGEN, OPGN, NKTR, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.53 +0.03 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 -0.01 (-0.28%)

As of 04:59 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Nektar Therapeutics NASDAQ:NKTR

$27.43 +0.17 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$27.16 -0.27 (-0.99%)

As of 04:22 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

OpGen NASDAQ:OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time